BS_ARBQDTT5
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 31.745
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1328919 | GTEX | — | 0.910 |
| 2 | TCGA-75-6212-01A-11R-1755-07 | — | cohortA1 | 0.870 |
| 3 | SRR1365828 | GTEX | — | 0.864 |
| 4 | ERR2598283 | fetal | fetal | 0.860 |
| 5 | SRR656167 | GTEX | — | 0.846 |
| 6 | SRR1459211 | GTEX | — | 0.846 |
| 7 | ERR2598329 | fetal | fetal | 0.845 |
| 8 | TCGA-OR-A5L5-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.841 |
| 9 | BS_5CMGN56B | low-grade glioma | — | 0.837 |
| 10 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.418 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.396 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.385 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.376 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.352 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.333 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.305 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.289 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.284 | Idelalisib | — uncovered |
| MYOGENESIS | 0.263 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.241 | Idelalisib | — uncovered |
| COMPLEMENT | 0.239 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.219 | Inavolisib | — uncovered |
| COAGULATION | 0.218 | Binimetinib | — uncovered |
| PEROXISOME | 0.214 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.208 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.206 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.201 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.199 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.186 | Idelalisib | — uncovered |